Device Trial Radar · NCT07223164
Validation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Oct 21, 2025
Primary completion
Oct 31, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Masimo CorporationPublic (MASI)
- Sponsor type
- Industry
- First posted
- Oct 31, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to validate the performance of Masimo Irregular Heartbeat Detection algorithm using Masimo SET® in detecting atrial fibrillation. The measurements will be compared to results obtained from Masimo Radius VSM®.
Conditions
- Healthy
Interventions
Masimo SET®Device
Pulse oximeter device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Specificity Measures the % of True Negatives for Atrial Fibrillation Detection in Participants With Normal Sinus Rhythm.Time frame: 1-2 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Masimo Corporation
Irvine, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.